KRT-232 and TKI Study in Chronic Myeloid Leukemia

Condition:   Chronic Myeloid Leukemia Interventions:   Drug: KRT-232;   Drug: Dasatinib;   Drug: Nilotinib Sponsor:   Kartos Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials